Literature DB >> 16291043

Herceptin and early breast cancer: a moment for caution.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16291043     DOI： 10.1016/S0140-6736(05)67670-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Seven years of feast, seven years of famine: boom to bust in the NHS?

Authors:  Alan Maynard; Andrew Street
Journal:  BMJ       Date:  2006-04-15

Review 2.  How much will Herceptin really cost?

Authors:  Ann Barrett; Tom Roques; Matthew Small; Richard D Smith
Journal:  BMJ       Date:  2006-11-25

3.  Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage.

Authors:  Paul M Wilson; Alison M Booth; Alison Eastwood; Ian S Watt
Journal:  J R Soc Med       Date:  2008-03       Impact factor: 5.344

4.  Media Hyping and the "Herceptin Access Story": An Analysis of Canadian and UK Newspaper Coverage.

Authors:  Julia Abelson; Patricia A Collins
Journal:  Healthc Policy       Date:  2009-02

5.  Media influence on Herceptin subsidization in Australia: application of the rule of rescue?

Authors:  Ross Mackenzie; Simon Chapman; Glenn Salkeld; Simon Holding
Journal:  J R Soc Med       Date:  2008-06       Impact factor: 5.344

Review 6.  HER2 status in breast cancer--an example of pharmacogenetic testing.

Authors:  Mark Kroese; Ron L Zimmern; Sarah E Pinder
Journal:  J R Soc Med       Date:  2007-07       Impact factor: 5.344
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.